Stock Analysis

3 Promising Penny Stocks With Market Caps Over US$100M

SEHK:2002
Source: Shutterstock

Global markets have been experiencing a mix of optimism and caution, with U.S. stock indexes nearing record highs despite inflationary pressures. For investors willing to explore beyond the large-cap landscape, penny stocks—often representing smaller or newer companies—remain an intriguing area for potential growth. Although the term 'penny stock' might seem outdated, these investments can still offer surprising value when backed by solid financials, presenting opportunities for those seeking hidden gems in the market.

Top 10 Penny Stocks

NameShare PriceMarket CapFinancial Health Rating
DXN Holdings Bhd (KLSE:DXN)MYR0.53MYR2.64B★★★★★★
Bosideng International Holdings (SEHK:3998)HK$3.87HK$44.43B★★★★★★
Warpaint London (AIM:W7L)£4.10£331.23M★★★★★★
Begbies Traynor Group (AIM:BEG)£0.938£149.49M★★★★★★
Datasonic Group Berhad (KLSE:DSONIC)MYR0.335MYR932.02M★★★★★★
Polar Capital Holdings (AIM:POLR)£4.98£480.06M★★★★★★
Hil Industries Berhad (KLSE:HIL)MYR0.84MYR278.83M★★★★★★
MGB Berhad (KLSE:MGB)MYR0.695MYR411.2M★★★★★★
Embark Early Education (ASX:EVO)A$0.79A$144.95M★★★★☆☆
Next 15 Group (AIM:NFG)£3.15£313.29M★★★★☆☆

Click here to see the full list of 5,690 stocks from our Penny Stocks screener.

Here's a peek at a few of the choices from the screener.

Millennium & Copthorne Hotels New Zealand (NZSE:MCK)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Millennium & Copthorne Hotels New Zealand Limited owns, operates, manages, leases, and franchises hotels in New Zealand and Australia with a market cap of NZ$342.81 million.

Operations: The company's revenue is primarily derived from hotel operations (NZ$109.52 million), with additional contributions from residential land development (NZ$32.85 million), residential property development (NZ$25.98 million), and investment property (NZ$2.58 million).

Market Cap: NZ$342.81M

Millennium & Copthorne Hotels New Zealand Limited, with a market cap of NZ$342.81 million, generates revenue mainly from hotel operations and property development. Despite its stable asset coverage over liabilities and absence of debt, the company faces challenges such as declining earnings over the past five years and reduced profit margins (2.2% compared to last year's 10.4%). Its share price has been highly volatile recently. A significant development is CDL Hotels Holdings' proposal to acquire the remaining stake in MCK for NZD 57.2 million, aiming to delist and privatize it by May 2025, pending regulatory approvals.

NZSE:MCK Debt to Equity History and Analysis as at Feb 2025
NZSE:MCK Debt to Equity History and Analysis as at Feb 2025

China Sunshine Paper Holdings (SEHK:2002)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: China Sunshine Paper Holdings Company Limited, along with its subsidiaries, is engaged in the production and sale of paper products both within the People's Republic of China and internationally, with a market cap of HK$2.40 billion.

Operations: The company's revenue is primarily derived from its paper products segment, including Coated-White TOP Linerboard (CN¥1.97 billion), Specialised Paper Products (CN¥1.71 billion), Corrugated Paper (CN¥1.81 billion), White Top Linerboard (CN¥1.57 billion), and Core Board (CN¥615.63 million), along with electricity and steam sales amounting to CN¥1.33 billion.

Market Cap: HK$2.4B

China Sunshine Paper Holdings, with a market cap of HK$2.40 billion, shows strengths in earnings growth and revenue diversification across its paper products segments. The company's earnings surged by 65.5% last year, surpassing the industry average, although its five-year trend shows a decline of 4.3% annually. Despite high debt levels (net debt to equity ratio at 62.8%), operating cash flow covers this well at 20.8%. The short-term assets fall short of covering liabilities but exceed long-term obligations significantly. Trading below estimated fair value suggests potential undervaluation; however, low return on equity and an inexperienced management team are concerns for investors.

SEHK:2002 Financial Position Analysis as at Feb 2025
SEHK:2002 Financial Position Analysis as at Feb 2025

Peijia Medical (SEHK:9996)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Peijia Medical Limited focuses on the research and development of transcatheter valve therapeutic and neuro interventional procedural medical devices, with a market cap of HK$2.71 billion.

Operations: The company generates revenue from its Neurointerventional Business, which accounts for CN¥309.30 million, and its Transcatheter Valve Therapeutic Business, contributing CN¥208.16 million.

Market Cap: HK$2.71B

Peijia Medical Limited, with a market cap of HK$2.71 billion, is focused on growth within its neurointerventional and transcatheter valve therapeutic businesses. Despite being unprofitable with a negative return on equity of -11.54%, the company has reduced losses over five years and forecasts revenue growth of 29.16% annually. Recent guidance projects revenue between RMB 610 million to RMB 630 million for 2024, driven by product line expansion and increased market share in China’s TAVR sector. The firm benefits from strong cash reserves exceeding debt, stable weekly volatility, and no recent shareholder dilution, but profitability remains elusive in the near term.

SEHK:9996 Financial Position Analysis as at Feb 2025
SEHK:9996 Financial Position Analysis as at Feb 2025

Where To Now?

  • Explore the 5,690 names from our Penny Stocks screener here.
  • Hold shares in these firms? Setup your portfolio in Simply Wall St to seamlessly track your investments and receive personalized updates on your portfolio's performance.
  • Maximize your investment potential with Simply Wall St, the comprehensive app that offers global market insights for free.

Looking For Alternative Opportunities?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com